243 related articles for article (PubMed ID: 35768005)
41. Machine learning approach using 18 F-FDG PET-based radiomics in differentiation of lung adenocarcinoma with bronchoalveolar distribution and infection.
Agüloğlu N; Aksu A; Unat DS
Nucl Med Commun; 2023 Apr; 44(4):302-308. PubMed ID: 36756766
[TBL] [Abstract][Full Text] [Related]
42. A Novel Radiogenomics Biomarker for Predicting Treatment Response and Pneumotoxicity From Programmed Cell Death Protein or Ligand-1 Inhibition Immunotherapy in NSCLC.
Chen M; Lu H; Copley SJ; Han Y; Logan A; Viola P; Cortellini A; Pinato DJ; Power D; Aboagye EO
J Thorac Oncol; 2023 Jun; 18(6):718-730. PubMed ID: 36773776
[TBL] [Abstract][Full Text] [Related]
43. Diagnostic test accuracy of
Seol HY; Kim YS; Kim SJ
Clin Radiol; 2021 Nov; 76(11):863.e19-863.e25. PubMed ID: 34261597
[TBL] [Abstract][Full Text] [Related]
44. New insight on the correlation of metabolic status on
Wang Y; Zhao N; Wu Z; Pan N; Shen X; Liu T; Wei F; You J; Xu W; Ren X
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1127-1136. PubMed ID: 31502013
[TBL] [Abstract][Full Text] [Related]
45. Prediction of disease-free survival by the PET/CT radiomic signature in non-small cell lung cancer patients undergoing surgery.
Kirienko M; Cozzi L; Antunovic L; Lozza L; Fogliata A; Voulaz E; Rossi A; Chiti A; Sollini M
Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):207-217. PubMed ID: 28944403
[TBL] [Abstract][Full Text] [Related]
46. Body Composition and Radiomics From 18 F-FDG PET/CT Together Help Predict Prognosis for Patients With Stage IV Non-Small Cell Lung Cancer.
Zhang Y; Tan W; Zheng Z; Wang J; Xing L; Sun X
J Comput Assist Tomogr; 2023 Nov-Dec 01; 47(6):906-912. PubMed ID: 37948365
[TBL] [Abstract][Full Text] [Related]
47. [CT-Based Weighted Radiomic Score Predicts Tumor Response to Immunotherapy in Non-Small Cell Lung Cancer].
Zhu ZC; Chen MJ; Song L; Wang JH; Hu G; Han W; Tan WX; Zhou Z; Sui X; Song W; Jin ZY
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2023 Oct; 45(5):794-802. PubMed ID: 37674467
[TBL] [Abstract][Full Text] [Related]
48. 18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer.
Zhang F; Wu X; Zhu J; Huang Y; Song X; Jiang L
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3250-3259. PubMed ID: 33630146
[TBL] [Abstract][Full Text] [Related]
49. Comprehensive
Cui Y; Lin Y; Zhao Z; Long H; Zheng L; Lin X
Front Immunol; 2022; 13():994917. PubMed ID: 36466929
[TBL] [Abstract][Full Text] [Related]
50. Value of pre-therapy
Zhang J; Zhao X; Zhao Y; Zhang J; Zhang Z; Wang J; Wang Y; Dai M; Han J
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1137-1146. PubMed ID: 31728587
[TBL] [Abstract][Full Text] [Related]
51. Negative Correlation Between
Wu L; Liu J; Wang S; Bai M; Wu M; Gao Z; Li J; Yu J; Liu J; Meng X
Front Endocrinol (Lausanne); 2022; 13():913631. PubMed ID: 35846323
[TBL] [Abstract][Full Text] [Related]
52. Applications of radiomics-based analysis pipeline for predicting epidermal growth factor receptor mutation status.
Liu Z; Zhang T; Lin L; Long F; Guo H; Han L
Biomed Eng Online; 2023 Feb; 22(1):17. PubMed ID: 36810090
[TBL] [Abstract][Full Text] [Related]
53. CD147-mediated glucose metabolic regulation contributes to the predictive role of
Li X; Fu Q; Zhu Y; Wang J; Liu J; Yu X; Xu W
Mol Carcinog; 2019 Feb; 58(2):247-257. PubMed ID: 30320488
[TBL] [Abstract][Full Text] [Related]
54.
Zhao Y; Ren J
Front Immunol; 2023; 14():1266843. PubMed ID: 38035081
[TBL] [Abstract][Full Text] [Related]
55. Machine learning based evaluation of clinical and pretreatment
Nakajo M; Jinguji M; Tani A; Yano E; Hoo CK; Hirahara D; Togami S; Kobayashi H; Yoshiura T
Abdom Radiol (NY); 2022 Feb; 47(2):838-847. PubMed ID: 34821963
[TBL] [Abstract][Full Text] [Related]
56. Utility of Volumetric Metabolic Parameters on Preoperative FDG PET/CT for Predicting Tumor Lymphovascular Invasion in Non-Small Cell Lung Cancer.
Li C; Tian Y; Shen Y; Wen B; He Y
AJR Am J Roentgenol; 2021 Dec; 217(6):1433-1443. PubMed ID: 33978465
[No Abstract] [Full Text] [Related]
57. 2-Deoxy-2-[fluorine-18] fluoro-d-glucose uptake on positron emission tomography is associated with programmed death ligand-1 expression in patients with pulmonary adenocarcinoma.
Kaira K; Shimizu K; Kitahara S; Yajima T; Atsumi J; Kosaka T; Ohtaki Y; Higuchi T; Oyama T; Asao T; Mogi A
Eur J Cancer; 2018 Sep; 101():181-190. PubMed ID: 30077123
[TBL] [Abstract][Full Text] [Related]
58. Preclinical evaluation and pilot clinical study of [
Ma X; Zhou X; Hu B; Li X; Yao M; Li L; Qin X; Li D; Yao Y; Hou X; Liu S; Chen Y; Wang Z; Zhou W; Li N; Zhu H; Jia B; Yang Z
Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):3838-3850. PubMed ID: 37555904
[TBL] [Abstract][Full Text] [Related]
59. CT radiomics analysis of lung cancers: Differentiation of squamous cell carcinoma from adenocarcinoma, a correlative study with FDG uptake.
Tomori Y; Yamashiro T; Tomita H; Tsubakimoto M; Ishigami K; Atsumi E; Murayama S
Eur J Radiol; 2020 Jul; 128():109032. PubMed ID: 32361604
[TBL] [Abstract][Full Text] [Related]
60. Predictive Value of 18F-Fluorodeoxyglucose Positron Emission Tomography or Positron Emission Tomography/Computed Tomography for Assessment of Occult Lymph Node Metastasis in Non-Small Cell Lung Cancer.
Seol HY; Kim YS; Kim SJ
Oncology; 2021; 99(2):96-104. PubMed ID: 32980838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
